AI assistant
AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2019
Feb 5, 2019
31580_dirs_2019-02-05_dec4ddf3-3c25-4142-844a-b867c46c9480.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGIOS PHARMACEUTICALS INC (AGIO)
CIK: 0001439222
Period of Report: 2019-02-01
Reporting Person: FOUSE JACQUALYN A (Director, Chief Executive Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-02-01 | Stock option (right to buy) | $53.87 | A | 350346 | Acquired | 2029-01-31 | Common stock (350346) | Direct |
| 2019-02-01 | Performance share units | $ | A | 42695 | Acquired | 2024-02-01 | Common stock (42695) | Direct |
Footnotes
F1: This option was granted on February 1, 2019. The shares underlying this option vest as to 25% of the shares on February 1, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F2: Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
F3: The performance share units vest if, during the five-year period beginning on February 1, 2019 and ending on February 1, 2024, the closing price of the issuer's common stock equals or exceeds $120 per share for at least 20 consecutive trading days at any time during such five-year period.